Boston Scientific (BSX) ebitda was $5.4B in FY2025 (+30% YoY). The tables below show the complete quarterly and annual ebitda history, sourced from SEC EDGAR 10-K and 10-Q filings.
Annual EBITDA
Fiscal Year
EBITDA
YoY
2025
$5.4B
+30%
2024
$4.2B
+8%
2023
$3.8B
+27%
2022
$3.0B
+20%
2021
$2.5B
+100%
2020
$1.3B
-54%
2019
$2.7B
+6%
2018
$2.6B
+12%
2017
$2.3B
+63%
2016
$1.4B
+124%
2015
$627M
+5%
2014
$596M
-41%
2013
$1.0B
+135%
2012
-$2.9B
-260%
2011
$1.8B
+331%
2010
$426M
+76%
2009
$242M
+144%
2008
-$556M
-146%
2007
$1.2B
Recent Quarterly EBITDA
Quarter
EBITDA
Q2 2026
$1.5B
Q1 2026
$1.5B
Q4 2025
$1.6B
Q3 2025
$1.2B
Q2 2025
$1.2B
Q1 2025
$1.3B
Q4 2024
$1.5B
Q3 2024
$911M
Q2 2024
$685M
Q1 2024
$1.0B
Q4 2023
$1.4B
Q3 2023
$860M
Source: BSX on EDGAR. Data from SEC EDGAR 10-K and 10-Q filings. Updated quarterly.